Skip to main content

Table 6 Comparison of the radiochemotherapy groups (30–40 mg/m2 of cisplatin weekly vs. 100 mg/m2 of cisplatin on days 1, 22 and 43) for acute and late adverse events

From: Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers

  Cisplatin weekly N patients (%) Cisplatin 100 mg/m2 N patients (%) P
Oral mucositis
 Grade ≥2 70 (93) 55 (95) 0.95
Skin reactions
 Grade ≥2 48 (64) 48 (83) 0.25
Hematotoxicity
 Grade ≥3 7 (9) 19 (33) 0.004
Renal failure
 Grade ≥2 2 (3) 12 (21) 0.004
Pneumonia/Sepsis
 Grade ≥3 1 (1) 7 (12) 0.033
Xerostomiaa
 Grade ≥2 28/60 (47) 34/58 (59) 0.44
Subcutaneous fibrosisa
 Grade ≥2 27/72 (38) 28/51 (55) 0.20
  1. anot available in all patients
  2. After Bonferroni correction for multiple tests (7 tests), p-values of <0.007 were considered significant
  3. Bold values represent significant p-values